StreetAlpha.app
Home › Stocks › AEON

AEON Biopharma, Inc. (AEON)

$0.12
▼ −15.59%
LAST CLOSE · NOV 17

AEON Biopharma is developing ABP-450, a botulinum toxin meant to be a biosimilar to Botox for therapeutic uses. It last closed at $0.12 on Nov 17, down 15.59% on the day.

AI Auto Pilots
Is AEON in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$47.6M
Valuation
Market cap
$10.0M
84.1M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.4M
At Sep 30
Debt
$2.0M
At Sep 30
Shareholder equity
$2.4M
Shares outstanding
84.1M
At Nov 13
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $8.2M$8.2MFY2021FY2022: −$52.6M−$52.6MFY2022FY2024: $42.0M$42.0MFY2024FY2025: −$39.2M−$39.2MFY2025

From AEON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated AEON in the past 90 days, not enough for a consensus
Average 12-month target
$2.00
▲ 1579.3% upside

Based on 1 analyst who set a price target on AEON in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.12.

Low $2.00Avg $2.00High $2.00
Blue marker: last close $0.12
Highest target$2.00
Average target$2.00
Lowest target$2.00
Latest rating changes
Lake StreetMaintained
Oct 1Buy$2
HC Wainwright & Co.Maintained
Aug 14Buy$1.20
DateFirmActionRatingPrice target
Oct 1Lake StreetMaintainedBuy$2
Aug 14HC Wainwright & Co.MaintainedBuy$1.20
Loading…

Technical Analysis

AEON · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 76% below its 20 day and 104% below its 50 day average. It is 418% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $0.11, and the nearest resistance the Pivot at $0.13.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 25.3%/day
Key levels
$1.4552 week high+1108.3%
$0.62200 day average+416.7%
$0.29100 day average+141.7%
$0.25Swing high (Oct 21)+108.3%
$0.2450 day average+100.0%
$0.2120 day average+75.0%
$0.15Pivot R1+25.0%
$0.13Pivot+8.3%
$0.12Last close
$0.1152 week low−8.3%
$0.10Pivot S1−16.7%
Indicators
RSI (14)27.91Oversold below 30Oversold
MACD-0.03Below its signal lineBearish
Stochastic10.2Near the bottom of its rangeOversold
ADX (14)27.5Trending down
Williams %R-94.1Oversold below −80, overbought above −20Oversold
CCI (20)-125.8Oversold below −100, overbought above 100Oversold
Rate of change−43.9%Change over 10 sessionsBearish
ATR (14)$0.03Typical daily range, 25.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AEON

What happened before

See how AEON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AEON usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AEON has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AEON in the last 90 days.

Loading…

See today’s whale options flow across the market →

AEON Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲13 buying vs 5 selling
  • ▲Held by funds +58.8 pts
  • ▲Funds holding +6
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2822+27.3%
In funds' top 10110.0%
Held by funds74.0%15.2%+58.8 pts
New / increased10 / 32 / 6+62.5%
Reduced / sold out1 / 41 / 40.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AEON institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AEON is in one of them and how their past AEON trades turned out.

AEON in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AEON in an article yet. Here's the latest on the wider market.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company based in Aliso Viejo, California. It is developing ABP-450, a botulinum toxin intended to serve as a biosimilar to Botox for therapeutic medical uses rather than cosmetic ones. The product is still in development, and the company is working toward a regulatory filing in the United States. Its intended customers are physicians and patients who use botulinum toxin treatments for medical conditions.

Headquarters
Aliso Viejo, CA